Vertice Pharma, a specialty pharmaceuticals company, has named Don DeGolyer as its new director and promoted Scott Meyers to chief executive officer, it was reported on Tuesday.
DeGolyer founded Vertice Pharma in 2015 with a focus to acquire specialty pharmaceutical companies and products, including both branded and generic products.
Meyers has been serving as chief operating officer for Vertice Pharma. He has more than 20 years of pharmaceutical experience with most recent position being vice president & general manager of Fougera Inc. He has also served as a consultant for McKinsey & Company's pharmaceutical practice and as a chemical engineer for Merck & Co.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US